Anaptysbio (ANAB) Receivables - Net (2016 - 2026)

Anaptysbio's Receivables - Net history runs 10 years deep, the most recent figure standing at $25.7 million for Q1 2026.

• Quarterly Receivables - Net rose 43.97% year-over-year to $25.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.7 million (up 43.97% YoY) and the FY2025 annual result came in at $33.8 million, down 16.96% from the prior year.
• Receivables - Net was $25.7 million for Q1 2026 at Anaptysbio, down from $33.8 million in the prior quarter.
• Across five years, Receivables - Net topped out at $75.7 million in Q3 2025 and bottomed at $921000.0 in Q1 2022.
• A 5-year average of $15.5 million and a median of $7.1 million in 2024 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2022 — Receivables - Net retreated 26.14% — and 2025, when it jumped 520.62%.
• Anaptysbio's Receivables - Net stood at $1.4 million in 2022, then surged by 382.8% to $6.9 million in 2023, then surged by 495.02% to $40.8 million in 2024, then decreased by 16.96% to $33.8 million in 2025, then slipped by 23.94% to $25.7 million in 2026.
• Business Quant data shows ANAB's Receivables - Net at $25.7 million in Q1 2026, $33.8 million in Q4 2025, and $75.7 million in Q3 2025.